EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Sex difference in survival benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer: A meta-analysis

Tingting Liu, Dandan Song, Jun Chen, Jiacheng Yao, Jiehao Liao, Jun Dang iD

PLOS One · 03.11.2026 · 21 (11) · e0361953

DOI: 10.1371/journal.pone.0361953 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift PLOS One, online erschienen am 03.11.2026. Verfasst von Tingting Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Hospital of China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit nennt 102 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whether sex influences the survival benefit of immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) remains uncertain.

Methods

We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and Scopus up to April 1, 2026, for randomized controlled trials (RCTs) comparing ICIs with chemotherapy and reporting overall survival (OS) or progression-free survival (PFS) stratified by sex. A random-effects model was used for meta-analysis.

Results

Sixty-three publications (reporting 42 phase 3 RCTs) involving 25,827 patients (18,772 male; 7,055 female) were included. Compared with chemotherapy, ICIs significantly improved both OS and PFS in males (OS: HR 0.74 [95% CI 0.71–0.78]; PFS: HR 0.59 [95% CI 0.54–0.64]) and females (OS: HR 0.83 [95% CI 0.77–0.90]; PFS: HR 0.76 [95% CI 0.66–0.86]). Pooled treatment-by-sex interaction analyses demonstrated significantly greater OS (interaction HR = 0.90 [95% CI 0.84–0.97]; P = 0.01) and PFS (interaction HR = 0.82 [95% CI 0.73–0.92]; P = 0.0006) benefits in males than in females. In subgroup analyses, sex‑based differences in OS reached statistical significance in patients receiving ICI monotherapy (P = 0.02), including those treated with anti‑PD‑1 monotherapy (P = 0.04) and those with PD‑L1 expression ≥50% (P = 0.02). However, these differences did not persist after the False Discovery Rate (FDR) correction (adjusted P = 0.07, 0.10, and 0.07, respectively). In contrast, sex‑based differences in PFS remained statistically significant after FDR correction in the ICI monotherapy (adjusted P = 0.001), anti‑PD‑1 monotherapy (adjusted P = 0.001), and PD‑L1 ≥ 50% (adjusted P = 0.004) subgroups. No significant sex‑based differences in either OS or PFS were observed among patients treated with ICI plus chemotherapy.

Conclusions

Although ICIs are superior to chemotherapy in both sexes, the PFS benefit of ICI monotherapy appears to be attenuated in females relative to males. Given the imbalances in baseline confounders coupled with the underrepresentation of females in the included trials, these findings should be interpreted with caution and warrant confirmation in future RCTs designed specifically to investigate sex‑based differences.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsCarcinoma, Non-Small-Cell LungLung NeoplasmsHumansFemaleMaleSex FactorsRandomized Controlled Trials as TopicProgression-Free Survival

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, The First Hospital of China Medical University, Shenyang, China.
  • Department of Radiation Oncology, Anshan Cancer Hospital, Anshan, China.
  • Department of Radiation Oncology, Xiang'an Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
  • Department of Radiation Oncology, Shenyang Tenth People's Hospital, Shenyang, China.
  • Department of Oncology, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.

ORCID-Profile: Jun Dang

Zitieren

APA

Liu, T., Song, D., Chen, J., Yao, J., Liao, J., & Dang, J. (2026). Sex difference in survival benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer: A meta-analysis. PLOS One, 21(11), e0361953. https://doi.org/10.1371/journal.pone.0361953

Vancouver

Liu T, Song D, Chen J, Yao J, Liao J, Dang J. Sex difference in survival benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer: A meta-analysis. PLOS One. 2026;21(11):e0361953. doi:10.1371/journal.pone.0361953

BibTeX
@article{Liu2026,
  author = {Liu, Tingting and Song, Dandan and Chen, Jun and Yao, Jiacheng and Liao, Jiehao and Dang, Jun},
  title = {Sex difference in survival benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer: A meta-analysis},
  journal = {PLOS One},
  year = {2026},
  volume = {21},
  number = {11},
  pages = {e0361953},
  doi = {10.1371/journal.pone.0361953}
}
Kostenlos starten →